vs
Pioneer Bancorp, Inc.（PBFS）与Xtant Medical Holdings, Inc.（XTNT）财务数据对比。点击上方公司名可切换其他公司
Xtant Medical Holdings, Inc.的季度营收约是Pioneer Bancorp, Inc.的1.3倍（$32.4M vs $25.0M），Pioneer Bancorp, Inc.净利率更高（82.1% vs 0.2%，领先81.9%），过去两年Pioneer Bancorp, Inc.的营收复合增速更高（144.9% vs 7.7%）
先锋银行控股公司（马里兰州）是一家美国银行控股企业，为先锋银行的母公司，主要面向马里兰州本地社区用户提供零售及商业银行服务，涵盖存款账户、住房与商业抵押贷款、消费贷款及小微企业融资等产品。
Xtant Medical Holdings是一家全球医疗技术企业，主营骨科生物制剂、神经外科器械及再生医学解决方案，为骨科与神经科诊疗机构提供脊柱手术耗材、骨再生产品等，服务覆盖北美、欧洲及亚太多个地区市场。
PBFS vs XTNT — 直观对比
营收规模更大
XTNT
是对方的1.3倍
$25.0M
净利率更高
PBFS
高出81.9%
0.2%
两年增速更快
PBFS
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $25.0M | $32.4M |
| 净利润 | $3.7M | $57.0K |
| 毛利率 | — | 54.9% |
| 营业利润率 | 21.3% | -2.9% |
| 净利率 | 82.1% | 0.2% |
| 营收同比 | — | 2.7% |
| 净利润同比 | — | 101.8% |
| 每股收益（稀释后） | $0.16 | $0.00 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PBFSXTNT
| Q4 25 | $25.0M | $32.4M | ||
| Q3 25 | $24.0M | $33.3M | ||
| Q2 25 | $24.4M | $35.4M | ||
| Q1 25 | $22.8M | $32.9M | ||
| Q4 24 | — | $31.5M | ||
| Q3 24 | $22.0M | $27.9M | ||
| Q2 24 | $20.9M | $29.9M | ||
| Q1 24 | $21.6M | $27.9M |
净利润PBFSXTNT
| Q4 25 | $3.7M | $57.0K | ||
| Q3 25 | $4.3M | $1.3M | ||
| Q2 25 | $6.5M | $3.5M | ||
| Q1 25 | $5.8M | $58.0K | ||
| Q4 24 | — | $-3.2M | ||
| Q3 24 | $6.3M | $-5.0M | ||
| Q2 24 | $3.9M | $-3.9M | ||
| Q1 24 | $4.7M | $-4.4M |
毛利率PBFSXTNT
| Q4 25 | — | 54.9% | ||
| Q3 25 | — | 66.1% | ||
| Q2 25 | — | 68.6% | ||
| Q1 25 | — | 61.5% | ||
| Q4 24 | — | 50.9% | ||
| Q3 24 | — | 58.4% | ||
| Q2 24 | — | 62.1% | ||
| Q1 24 | — | 62.1% |
营业利润率PBFSXTNT
| Q4 25 | 21.3% | -2.9% | ||
| Q3 25 | 23.4% | 7.6% | ||
| Q2 25 | 33.3% | 13.1% | ||
| Q1 25 | 32.5% | 3.2% | ||
| Q4 24 | — | -6.0% | ||
| Q3 24 | 37.2% | -13.5% | ||
| Q2 24 | 24.1% | -9.8% | ||
| Q1 24 | 28.1% | -12.4% |
净利率PBFSXTNT
| Q4 25 | 82.1% | 0.2% | ||
| Q3 25 | 18.0% | 3.9% | ||
| Q2 25 | 26.4% | 10.0% | ||
| Q1 25 | 25.3% | 0.2% | ||
| Q4 24 | — | -10.0% | ||
| Q3 24 | 28.7% | -18.0% | ||
| Q2 24 | 107.4% | -12.9% | ||
| Q1 24 | 21.9% | -15.8% |
每股收益（稀释后）PBFSXTNT
| Q4 25 | $0.16 | $0.00 | ||
| Q3 25 | $0.18 | $0.01 | ||
| Q2 25 | $0.26 | $0.02 | ||
| Q1 25 | $0.23 | $0.00 | ||
| Q4 24 | — | $-0.02 | ||
| Q3 24 | $0.25 | $-0.04 | ||
| Q2 24 | $0.15 | $-0.03 | ||
| Q1 24 | $0.19 | $-0.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $17.1M |
| 总债务越低越好 | — | $11.0M |
| 股东权益账面价值 | $323.9M | $51.0M |
| 总资产 | $2.2B | $94.1M |
| 负债/权益比越低杠杆越低 | — | 0.22× |
8季度趋势，按日历期对齐
现金及短期投资PBFSXTNT
| Q4 25 | — | $17.1M | ||
| Q3 25 | — | $10.4M | ||
| Q2 25 | — | $6.9M | ||
| Q1 25 | — | $5.0M | ||
| Q4 24 | — | $6.2M | ||
| Q3 24 | — | $6.6M | ||
| Q2 24 | — | $5.4M | ||
| Q1 24 | — | $4.5M |
总债务PBFSXTNT
| Q4 25 | — | $11.0M | ||
| Q3 25 | — | $17.4M | ||
| Q2 25 | — | $22.3M | ||
| Q1 25 | — | $22.2M | ||
| Q4 24 | — | $22.0M | ||
| Q3 24 | — | $19.1M | ||
| Q2 24 | — | $21.8M | ||
| Q1 24 | — | $16.8M |
股东权益PBFSXTNT
| Q4 25 | $323.9M | $51.0M | ||
| Q3 25 | $314.2M | $50.4M | ||
| Q2 25 | $314.2M | $48.5M | ||
| Q1 25 | $310.7M | $43.9M | ||
| Q4 24 | — | $43.0M | ||
| Q3 24 | $303.8M | $45.7M | ||
| Q2 24 | $296.5M | $45.0M | ||
| Q1 24 | $289.0M | $47.7M |
总资产PBFSXTNT
| Q4 25 | $2.2B | $94.1M | ||
| Q3 25 | $2.2B | $106.3M | ||
| Q2 25 | $2.1B | $103.5M | ||
| Q1 25 | $2.1B | $95.8M | ||
| Q4 24 | — | $93.8M | ||
| Q3 24 | $2.0B | $98.9M | ||
| Q2 24 | — | $95.6M | ||
| Q1 24 | $2.0B | $93.9M |
负债/权益比PBFSXTNT
| Q4 25 | — | 0.22× | ||
| Q3 25 | — | 0.35× | ||
| Q2 25 | — | 0.46× | ||
| Q1 25 | — | 0.51× | ||
| Q4 24 | — | 0.51× | ||
| Q3 24 | — | 0.42× | ||
| Q2 24 | — | 0.48× | ||
| Q1 24 | — | 0.35× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $11.1M | $5.4M |
| 自由现金流经营现金流 - 资本支出 | — | $5.0M |
| 自由现金流率自由现金流/营收 | — | 15.4% |
| 资本支出强度资本支出/营收 | — | 1.2% |
| 现金转化率经营现金流/净利润 | 2.97× | 94.39× |
| 过去12个月自由现金流最近4个季度 | — | $10.2M |
8季度趋势，按日历期对齐
经营现金流PBFSXTNT
| Q4 25 | $11.1M | $5.4M | ||
| Q3 25 | $3.9M | $4.6M | ||
| Q2 25 | $5.1M | $1.3M | ||
| Q1 25 | $-3.5M | $1.3M | ||
| Q4 24 | — | $665.0K | ||
| Q3 24 | $1.9M | $-1.7M | ||
| Q2 24 | $9.0M | $-5.1M | ||
| Q1 24 | $3.3M | $-5.8M |
自由现金流PBFSXTNT
| Q4 25 | — | $5.0M | ||
| Q3 25 | — | $4.2M | ||
| Q2 25 | — | $910.0K | ||
| Q1 25 | — | $87.0K | ||
| Q4 24 | — | $-7.0K | ||
| Q3 24 | — | $-3.8M | ||
| Q2 24 | — | $-5.7M | ||
| Q1 24 | — | $-6.5M |
自由现金流率PBFSXTNT
| Q4 25 | — | 15.4% | ||
| Q3 25 | — | 12.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | -0.0% | ||
| Q3 24 | — | -13.7% | ||
| Q2 24 | — | -18.9% | ||
| Q1 24 | — | -23.4% |
资本支出强度PBFSXTNT
| Q4 25 | — | 1.2% | ||
| Q3 25 | — | 1.3% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 3.6% | ||
| Q4 24 | — | 2.1% | ||
| Q3 24 | — | 7.5% | ||
| Q2 24 | — | 1.9% | ||
| Q1 24 | — | 2.8% |
现金转化率PBFSXTNT
| Q4 25 | 2.97× | 94.39× | ||
| Q3 25 | 0.90× | 3.53× | ||
| Q2 25 | 0.78× | 0.36× | ||
| Q1 25 | -0.61× | 22.03× | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.30× | — | ||
| Q2 24 | 2.30× | — | ||
| Q1 24 | 0.70× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PBFS
暂无分部数据
XTNT
| Orthobiologics | $18.3M | 57% |
| Spinal Implant | $9.4M | 29% |
| License Revenue | $4.6M | 14% |
